Your session is about to expire
← Back to Search
HCW9218 for Advanced Solid Cancers
Study Summary
This trial is testing a new drug, HCW9218, to see if it is effective in treating advanced/metastatic solid tumor cancer. The drug is administered by injection and is a fusion protein complex that activates IL-15R signaling on effector immune cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My lung function is more than half of what is expected.I am currently being treated for an autoimmune disease.I am currently on IV antibiotics for an infection.My cancer has spread, isn't pancreatic/brain cancer, and 2 treatments have failed.I have had cancer before, but it fits the exceptions.I am not taking any herbal supplements that affect liver enzymes.I haven't had any major blood vessel problems in the last 6 months.Any side effects from my previous treatments are mild or gone.I have been treated with specific drugs targeting my condition before.I might have cancer that has spread to my brain and hasn't been treated.I haven't had any cancer treatment in the last 14 days.My organs are functioning well, as tested within the last 2 weeks.I am fully active or can carry out light work.I have had an organ transplant from another person.I am 18 years old or older.I will use effective birth control for 28 days after my last dose.
- Group 1: Administer HCW9218
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has HCW9218 received clearance from the Food and Drug Administration?
"HCW9218 is classified as a Phase 1 trial, so our team at Power assigned it a score of 1 due to the sparse clinical data supporting safety and efficacy."
Are there any remaining slots available in this medical experiment?
"According to the details available on clinicaltrials.gov, this trial has been actively recruiting participants since it was posted on April 1st 2022 and last updated a little over two weeks later."
What is the aggregate figure of participants taking part in this experiment?
"Absolutely. Evident on clinicaltrials.gov, the medical trial was first announced on April 1st 2022 and was revised most recently in mid-April; The research team is currently recruiting 24 people from a single clinic for participation."
Share this study with friends
Copy Link
Messenger